[Effects of high plating densities on in vitro and in vivo differentiation capability of immortalized human mesenchymal stem cells].
Sun ZL., Zhang YZ.
Laboratory Study, published in Zhonghua Yi Xue Za Zhi (2013) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Zhonghua Yi Xue Za Zhi (2013)
- Country
- China
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 24534322
Abstract (original English)
To determine whether different cell plating densities could influence the potential differentiation of immortalized human mesenchymal stem cells (hMSC-TERT). Extensive characterization was performed for two independent cell lines derived from parental hMSC-TERT cell line based on different plating densities during expansion in culture: 1: 2 (hMSC-TERT2) and 1: 20 (hMSC-TERT20). Their adipocytic, osteogenic, neuronal differentiation potential in vitro and multidirectional differentiation potential in vivo were analyzed by immunohistochemistry for pathologic tissue markers. hMSC-TERT2 formed cellular adipose foci and mineralized tuberculum after in vitro induction while hMSC-TERT20 showed adipocytes but no adipose foci or mineralized tuberculum. The positive rate of hMSC-TERT2 formed tissues on VIM, GFAP and LCA (89.17% ± 5.97%, 72.5% ± 10.11% and 76.67% ± 11.15%) under SCID murine skin were more than that of hMSC-TERT20 formed tissues (0.33% ± 0.65%, 9.58% ± 4.29% and 22.08% ± 6.95%). The cell lines derived at high plating density may have more powerful differentiation potential in vitro and in vivo than those derived at low cell plating density.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.